Acute Pharyngitis Global Market Report 2025

The acute pharyngitis market size has grown strongly in recent years. It will grow from $2.67 billion in 2024 to $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to several factors, including the rising incidence of viral and bacterial infections, which have contributed to the increased demand for treatments. Additionally, growing healthcare awareness has led to earlier diagnosis and better management of acute pharyngitis. Advancements in diagnostic technologies have made it easier to identify the cause of infections, while the rising number of pediatric cases has further driven the market. Moreover, an increase in environmental pollutants and allergens has contributed to a higher prevalence of throat-related conditions.

The acute pharyngitis market size is expected to see rapid growth in the next few years. It will grow to $3.98 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The projected growth during the forecast period can be linked to factors such as the increasing prevalence of influenza and streptococcal infections, a stronger emphasis on personalized medicine, higher adoption rates of rapid diagnostic tests, advancements in healthcare infrastructure, and broader healthcare access in emerging markets. Key trends expected to shape the forecast period include a shift toward over-the-counter treatments, a rise in the use of combination therapies, the expansion of telemedicine for diagnosing pharyngitis, growing popularity of natural and alternative remedies, and an increasing preference for self-care and home treatments.

The increasing prevalence of influenza is expected to drive the growth of the acute pharyngitis market. Influenza is caused by infection with influenza viruses, which spread through respiratory droplets from coughs, sneezes, or contact with contaminated surfaces. Factors such as seasonal changes, low vaccination rates, increased human mobility, viral mutations, and weakened immunity in certain populations contribute to the rise in influenza cases. Acute pharyngitis treatment helps alleviate throat inflammation and pain in influenza patients, reducing discomfort while swallowing, preventing secondary bacterial infections, and supporting overall recovery. When combined with antiviral medications, proper hydration, and rest, these treatments enhance the body's ability to combat the influenza virus. For example, as of February 2025, the Centers for Disease Control and Prevention (CDC) reported that 31.6% of clinical lab tests for influenza were positive, up from 29.4% the previous week and 18.6% at the start of the year. This increase in influenza cases is contributing to the growth of the acute pharyngitis market.

Companies in the acute pharyngitis market are focusing on developing antibiotics to treat bacterial infections more effectively and reduce antibiotic resistance. Antibiotics are essential for treating acute pharyngitis caused by bacterial infections, such as streptococcus pyogenes, by eliminating the bacteria, reducing symptoms, and preventing complications such as rheumatic fever. For example, in February 2022, Alembic Pharmaceuticals Limited, an India-based company, received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for Clarithromycin tablets, available in 250 mg and 500 mg dosages. This macrolide antibiotic is used to treat mild to moderate bacterial infections, including pharyngitis, tonsillitis, community-acquired pneumonia, and chronic bronchitis. The approval highlights the importance of effective antimicrobial treatments in managing acute pharyngitis and other related bacterial infections.

In November 2022, TPG Inc., a US-based private equity firm, acquired a majority stake in iNova Pharmaceuticals for $1.3 billion. With this acquisition, TPG Inc. aims to accelerate growth, expand market reach, and enhance its product offerings in the healthcare sector, particularly in Southeast and North Asia. iNova Pharmaceuticals, based in Singapore, focuses on providing over-the-counter products designed to relieve pharyngitis symptoms, such as throat lozenges and pain relievers.

Major players in the acute pharyngitis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Glaxo Smithkline Pharmaceuticals Ltd, F. Hoffmann-La Roche AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz Group AG, Bitop AG, Hikma Pharmaceuticals, Lupin Limited, Alkem Laboratories Ltd., MEDICE Arzneimittel Pütter GmbH & Co. KG, MCM Klosterfrau Vertriebsgesellschaft mbH.

North America was the largest region in the acute pharyngitis market in 2024. The regions covered in acute pharyngitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Acute Pharyngitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acute pharyngitis is the inflammation of the pharynx, a part of the throat located behind the mouth and nasal cavity, commonly causing a sore throat along with symptoms such as fever, headache, and swollen lymph nodes. This condition is most often caused by viral infections, though bacterial and fungal infections can also be responsible.

The primary treatments for acute pharyngitis include antibiotics, antivirals, over-the-counter (OTC) medications, corticosteroids, anti-inflammatory drugs, and alternative remedies. Antibiotics are used to treat bacterial infections by killing bacteria or inhibiting their growth. These treatments are distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies, with key end-users including hospitals, homecare settings, specialty centers, and other healthcare providers.

The acute pharyngitis market research report is one of a series of new reports that provides acute pharyngitis market statistics, including acute pharyngitis industry global market size, regional shares, competitors with an acute pharyngitis market share, detailed acute pharyngitis market segments, market trends and opportunities, and any further data you may need to thrive in the acute pharyngitis industry. This acute pharyngitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute pharyngitis market consists of revenues earned by entities by providing services such as diagnostic testing services, pharmaceutical dispensing services, and preventive and vaccination services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute pharyngitis market also includes sales of penicillin, amoxicillin, azithromycin, throat gargles and rinses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.